Table 2.
Regression analyses of inpatient primary outcomes.a
|
|
P1b (N=186) | P2c (N=211) | P5d (N=126) | N4e (N=193) | N5f (N=919) | |||||||||||||||
|
|
Compliance, % (n/N) | ORg (95% CI) | P value | Compliance, % (n/N) | OR (95% CI) | P value | Compliance, % (n/N) | OR (95% CI) | P value | Compliance, % (n/N) | OR (95% CI) | P value | Compliance, % (n/N) | OR (95% CI) | P value | |||||
| Control variables | ||||||||||||||||||||
|
|
SOFAh score | —i | — | — | N/Aj | 0.973 (0.863-1.096) | .65 | N/A | 1.355 (1.064-1.787) | .02 | N/A | 1.164 (0.753-1.879) | .51 | N/A | 0.772 (0.608-0.975) | .03 | ||||
|
|
Age | N/A | 0.973 (0.944-1.000) | .06 | N/A | 0.952 (0.914-0.987) | .01 | N/A | 0.995 (0.953-1.042) | .82 | N/A | 1.048 (1.008-1.093) | .02 | N/A | 0.993 (0.979-1.007) | .34 | ||||
| Group variables | ||||||||||||||||||||
|
|
Control group | 16.3 (15/92) | Refk | N/A | 49.2 (29/59) | Ref | N/A | 21.6 (19/88) | Ref | N/A | 85.3 (110/129) | Ref | N/A | 90.0 (531/590) | Ref | N/A | ||||
|
|
Intervention group | 45.7 (43/94) | 4.004 (1.828-9.202) | <.001 | — | — | — | — | — | — | — | — | — | — | — | — | ||||
|
|
Without teleconsultation | — | — | — | 81.8 (108/132) | 4.718 (2.032-11.563) | <.001 | 0.00 (0/14) | 0.000 (0.000, 1.032) | .99 | 93.9 (31/33) | 9.372 (1.519-111.467) | .04 | 84.9 (163/192) | 0.990 (0.542-1.834) | .97 | ||||
|
|
With teleconsultation | — | — | — | 90.0 (18/20) | 6.822 (1.271-56.607) | .04 | 25.0 (6/24) | 1.135 (0.179, 7.493) | .89 | 80.6 (25/31) | 1.744 (0.326, 12.861) | .54 | 92.1 (125/137) | 1.463 (0.666-3.416) | .36 | ||||
aEach model also controlled for hospital specific effects, which are not reported individually in this table; CIs were calculated based on profile likelihood estimation.
bPrimary outcome P1: Imperatively start antimicrobial treatment and remove the focus on Staphylococcus aureus bloodstream infection.
cPrimary outcome P2: Critically ill patients with signs of infection need early appropriate antibiotic therapy.
dPrimary outcome P5: Prefer oral formulations of highly bioavailable antimicrobials whenever possible.
ePrimary outcome N4: Do not prolong prophylactic administration of antibiotics in patients after they have left the operating room.
fPrimary outcome N5: Do not treat an elevated C‐reactive protein or procalcitonin level with antibiotics in patients without signs of infection.
gOR: odds ratio.
hSOFA: Sequential Organ Failure Assessment.
iDue to differences model specifications, the respective variables were not included in all models.
jN/A: not applicable.
kRef: reference group.